anti-CCN2 bispecific antibodies (WuXi Biologics/Aravive)

N/A

Report date: 2025/03/14 16:45:00

Base Information

Drug Nameanti-CCN2 bispecific antibodies (WuXi Biologics/Aravive)
Drug Alias Nameanti-CCN2 bispecific antibodies (Aravive/WuXi Biologics)anti-CTGF bispecific antibodies (Aravive/WuXi Biologics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionConnective tissue growth factor inhibitors
TargetsConnective tissue growth factor
Therapy Area/IndicationsFibrosisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuxi Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAravive IncWuxi Biologics Co Ltd
Inactive CompaniesN/A
Active IndicationsFibrosisNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A